In a colitis experiment on mice, the GPR68 small molecule inhibitor ogremorphin (OGM) was used to diminish pro-inflammatory cytokine levels, including TNF and IL-6, and fibrotic factor TGF-β1, and reduce the degree of colon inflammation in mice, suggesting that GPR68 may regulate the inflammatory response through the release of regulatory factors/inflammatory factors (de Vallière et al., 2021). Here, GPR68 is linked to colitis.